Address: 125284 Москва, ул. Беговая д. 3, строение 1,Russia
Tel: +7 (495) 799-56-99
AstraZeneca has had a presence in Russia since 1993 when representative offices of Swedish Astra AB and British Zeneca were opened. In 1999, these two companies merged and a new ambitious player on the market was formed – AstraZeneca.
AstraZeneca now employs more than 1,000 people across 68 Russian cities. Around 40 of our original products are licensed for sale in Russia.
In 2010, AstraZeneca achieved sales in Russia of more than $200 million and is targeting double-digit growth over the next five years. AstraZeneca has leading position in the hospital and oncology segments and is the fastest-growing company in retail pharmaceutical sector with Nexium and Symbicort as its best sellers.
Achieving continuing growth in Russia is a strategic priority for AstraZeneca. The Marketing Company is committed to contributing to the development of the innovative pharmaceutical sector in Russia, helping to meet the goals of the Russian Government’s Pharma 2020 strategy.
As part of our growth strategy, AstraZeneca is investing more than $150 million in building a new full cycle manufacturing plant in the Kaluga Region. At Phase I (packing) in 2013 the site’s capacity will be 16 million packs per year including medicines for cardiology, oncology, gastroenterology, neuroscience and respiratory. By 2015 full cycle production will be launched with the capacity to produce 500 mln tablets per year.
As well as investing in a new production plant, the company is committed to innovative pharmaceutical research and development in Russia. At the moment AstraZeneca has collaborations with over 150 research institutes to conduct phase II-IV clinical trials.
The company has signed Memoranda of Understanding with the Russian Venture Company and Skolkovo Foundation to help develop the country’s infrastructure for biomedicine and bio-pharmaceutics. A major component of these joint initiatives is the company’s Virtual Research Institute – Avangard Znaniy – a programme supporting promising Russian medical and pharmaceutical researchers.
Being a socially responsible company, AstraZeneca implements a number of large-scale patient health and disease awareness CSR projects, such as “Save Your Hearts” in cardiology and “World Mental Health Day” in neurology.
Oncology segments and is the fastest-growing company in retail pharmaceutical sector with Nexium and Symbicort as its best sellers.
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What…
Last time Focus Reports met with you in 2006, the Russian pharmaceutical industry had enjoyed five straight years…
There is a long history of trade between Russia and Britain. The Chamber of Commerce started in 1916. Can you…